Over the past 12 months, 8 insiders at Keros Therapeutics, Inc. filed 17 open-market SEC Form 4 transactions on KROS: 5 purchases worth $66K and 12 sales worth $181.0M. Insiders have been net sellers over this period. The most recent filing was on Jul 15, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 26 | Jean Jacques BienaimeDirector | BUY | 1.0K | $10.61 | $11K |
| Jun 15, 26 | Jean Jacques Bienaime | BUY | 1.0K | $10.19 | $10K |
| Jun 4, 26 | Nima Farzan | SELL | 2.6K | $10.73 | $28K |
| May 15, 26 | Jean Jacques Bienaime | BUY | 1.0K | $10.58 | $11K |
| Apr 15, 26 | Jean Jacques Bienaime | BUY | 1.0K | $11.70 | $12K |
| Mar 9, 26 | Jean Jacques BienaimeDirector | BUY | 2.0K | $11.21 | $22K |
| Feb 19, 26 | Jasbir SeehraCHIEF EXECUTIVE OFFICER | SELL | 7.0K | $16.17 | $113K |
| Feb 18, 26 | Esther ChoSVP, General Counsel | SELL | 4.7K | $16.35 | $78K |
| Feb 18, 26 | Lorena Raquel LernerChief Science Officer | SELL | 3.9K | $16.35 | $63K |
| Feb 18, 26 | Keith RegnanteCHIEF FINANCIAL OFFICER | SELL | 4.7K | $16.35 | $77K |
| Oct 15, 25 | Pontifax (china) IV L.p.TenPercentOwner | SELL | 2.28M | $17.75 | $40.6M |
| Oct 15, 25 | Daniel SchneebergerTenPercentOwner | SELL | 4.39M | $17.75 | $77.9M |
| Apr 9, 25 | Adar1 Partners, LpTenPercentOwner | BUY | 500.0K | $10.33 | $5.2M |
| Aug 13, 24 | Carl L GordonDirector | SELL | 220.6K | $44.01 | $9.7M |
| Aug 13, 24 | Orbimed Genesis Gp LlcDirector | SELL | 220.6K | $44.01 | $9.7M |
| Jan 4, 24 | Keith RegnanteCHIEF FINANCIAL OFFICER | SELL | 40.0K | $45.29 | $1.8M |
| Nov 4, 23 | Keith RegnanteChief Financial Officer | SELL | 40.0K | $45.29 | $1.8M |
| Jun 9, 23 | Keith RegnanteChief Financial Officer | SELL | 16.0K | $47.25 | $720K |
| Jun 8, 23 | Keith RegnanteChief Financial Officer | SELL | 17.3K | $48.65 | $825K |
| Jul 15, 22 | Jennifer LacheyChief Scientific Officer | SELL | 46.0K | $30.00 | $1.4M |
| Jul 13, 22 | Jennifer LacheyChief Scientific Officer | SELL | 1.9K | $30.00 | $57K |
| May 11, 22 | Jennifer LacheyChief Scientific Officer | SELL | 3.4K | $45.45 | $140K |
| Apr 11, 22 | Jennifer LacheyChief Scientific Officer | SELL | 2.3K | $64.15 | $147K |
| Apr 6, 22 | Christopher RovaldiChief Operating Officer | SELL | 1.7K | $65.00 | $112K |
| Apr 4, 22 | Jennifer LacheyChief Scientific Officer | SELL | 8.0K | $60.00 | $477K |
| Apr 1, 22 | Christopher RovaldiChief Operating Officer | SELL | 366 | $58.83 | $21K |
| Mar 11, 22 | Jennifer LacheyChief Scientific Officer | SELL | 1.1K | $54.54 | $56K |
| Feb 11, 22 | Jennifer LacheyChief Scientific Officer | SELL | 1.4K | $53.10 | $72K |
| Jan 11, 22 | Jennifer LacheyChief Scientific Officer | SELL | 1.2K | $54.45 | $64K |
| Jan 5, 22 | Jennifer LacheyChief Scientific Officer | SELL | 2.6K | $60.00 | $159K |
| Jan 5, 22 | Julius KnowlesDirector | SELL | 1.4K | $59.00 | $79K |
| Jan 4, 22 | Julius KnowlesDirector | SELL | 4.2K | $58.86 | $241K |
| Jan 3, 22 | Julius KnowlesDirector | SELL | 5.2K | $59.40 | $309K |
| Dec 15, 21 | Jennifer LacheyChief Scientific Officer | SELL | 735 | $50.00 | $37K |
| Dec 13, 21 | Jennifer LacheyChief Scientific Officer | SELL | 1.5K | $53.64 | $76K |
| Dec 2, 21 | Julius KnowlesDirector | SELL | 8.7K | $54.67 | $471K |
| Dec 1, 21 | Julius KnowlesDirector | SELL | 5.2K | $56.27 | $283K |
| Nov 11, 21 | Jennifer LacheyChief Scientific Officer | SELL | 4.6K | $59.78 | $273K |
| Nov 10, 21 | Jennifer LacheyChief Scientific Officer | SELL | 15.9K | $60.00 | $954K |
| Nov 4, 21 | Jennifer LacheyChief Scientific Officer | SELL | 10.6K | $50.00 | $530K |
| Nov 3, 21 | Julius KnowlesDirector | SELL | 6.1K | $42.45 | $253K |
| Nov 2, 21 | Julius KnowlesDirector | SELL | 3.3K | $43.04 | $137K |
| Nov 1, 21 | Julius KnowlesDirector | SELL | 7.3K | $42.43 | $312K |
| Oct 20, 21 | Julius KnowlesDirector | SELL | 2.2K | $38.31 | $86K |
| Oct 19, 21 | Julius KnowlesDirector | SELL | 2.0K | $38.49 | $77K |
| Oct 18, 21 | Julius KnowlesDirector | SELL | 8.3K | $38.46 | $311K |
| Oct 15, 21 | Julius KnowlesDirector | SELL | 3.0K | $40.60 | $118K |
| Oct 14, 21 | Julius KnowlesDirector | SELL | 2.7K | $40.13 | $106K |
| Oct 5, 21 | Julius KnowlesDirector | SELL | 1.6K | $40.03 | $63K |
| Oct 4, 21 | Julius KnowlesDirector | SELL | 2.3K | $40.06 | $91K |
Over the past 12 months, insiders at Keros Therapeutics, Inc. filed 5 open-market purchases worth $66K and 12 sales worth $181.0M on KROS, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 15, 26.
The largest recent open-market KROS insider purchase in our data was $5.2M by Adar1 Partners, Lp, TenPercentOwner, filed on Apr 9, 25.
8 different insiders at Keros Therapeutics, Inc. filed open-market SEC Form 4 transactions on KROS over the last 12 months.
InsiderTape plots every KROS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Keros Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →